["Neurorestorative" cell therapy in Parkinson's disease: an unresolved debate].
At present there is great enthusiasm over the perspectives deriving from so-called cell therapy in Parkinson's disease. This enthusiasm has spread beyond the ambit of the medical community, reaching the general public, and has been fuelled by a considerable ethical and political debate, sidestepping the need for a really scientific analysis of the real qualities and limitations of treatment with stem-cells in neurodegenerative diseases. Parkinson's disease is frequently observed from a simplistic perspective, as a mere neurodegeneration of the nigrostriatal dopaminergic pathway. This viewpoint encompasses different designs that tend to replace the lack of dopamine in the striatum through the use of different types of cell therapy. In this respect, it is important to indicate, on the one hand, the multisystemic and generalised nature of the disease and, on the other, the progressive character of the neurodegenerative process of Parkinson's disease. With this approach, to claim that the mere replacement of striatal dopamine through replacement cell therapy can correct the generalised and progressive character of the disease is a fanciful aspiration, which can only contribute to generating unfounded expectations in the general public. This article attempts to set out from a purely scientific point of view the doubts over the expectations created by these new therapeutic designs.
Lanciego
J L
JL
Centro de investigación médica aplicada, Facultad de Medicina, Universidad de Navarra, Pamplona, Navarra, 31008, Spain.
Gonzalo
N
N
Rodríguez-Oroz
M C
MC
Rodríguez
M
M
Obeso
J A
JA
D017690:Cell Transplantation; D006801:Humans; D019635:Neurosurgical Procedures; D010300:Parkinson Disease / Q000601:surgery*